Specialty Pharmacy News

Image description

PhRMA brings scientists to Capitol Hill

The Pharmaceutical Research and Manufacturers of America (PhRMA) on Wednesday brought 60 of its member companies’ researchers to Capitol Hill for meetings with members of Congress.

Image description

Diplomat extends oncology campaign

The company is encouraging people to share their stories about experiences with cancer — either their personal experience or that of someone they know — using the hashtag #CancerTaughtMe. 

Image description

ScriptPro streamlines will-call, documentation pain points

Pharmacy technology company ScriptPro is positioning itself as a provider of solutions that will ease common pain points that come with increased script volume and the influx of paperwork from clinical services with two forthcoming innovations that address pharmacy documentation needs and the will-call process.

Image description

Allergan expands eye care pipeline with acquisition

The acquisition saw Allergan pay RetroSense Therapeutics a $60 million upfront payment, with the promise of potential regulatory and commercialization milestone payments for the company’s lead development program, RST-001 — a potential therapy for retinitis pigmentosa. 

Image description

Report: Biosmilar regulatory pathway promising but there are sill barriers

Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. As biosimilars gain FDA approval, patent issues remain a barrier and the exorbitant R&D cost prevent significant price disparities. Accordingly, insurers may be slow to add biosimilars to the formulary, The National Law Review suggested. (The National Law Review)